SCHEMBL6979144

SCHEMBL6979144

CNc1ccc(COc2cccc(F)c2)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.44
MAOB P27338 5/20 0.43
MAOA P21397 1/20 0.43
NR4A2 P43354 2/20 0.43
NR4A1 P22736 1/20 0.43
NR4A3 Q92570 1/20 0.43
MRGPRX4 Q96LA9 1/20 0.42
INPPL1 O15357 1/20 0.42
HTR6 P50406 1/20 0.41
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
MAPT P10636 2/20 0.41
DCPS Q96C86 1/20 0.41
HTR1A P08908 1/20 0.41
ALDH1A1 P00352 1/20 0.41
NCOA1 Q15788 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
SLC6A3 Q01959 1/20 0.41
RAB9A P51151 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14380761 0.87 FFAR1 (0.43) MAOBMAOANR4A2NR4A1NR4A3
SCHEMBL14380641 0.86 DCPS (0.43) MAOBMAOANR4A2NR4A1NR4A3
SCHEMBL6956760 0.86 MAOB (0.46) MAOBMAOANR4A2NR4A1NR4A3
SCHEMBL9975347 0.84 MAPT (0.54) APPMAOBMAOANR4A2NR4A1
SCHEMBL6979333 0.82 HTR6 (0.46) MAOBMAOANR4A2NR4A1NR4A3
SCHEMBL9975350 0.81 NR1H4 (0.45) APPNR4A2NR4A1NR4A3MRGPRX4
SCHEMBL13712203 0.80 MAOB (0.47) MAOBMAOANR4A2NR4A1NR4A3
SCHEMBL2983086 0.79 MAOB (0.50) MAOBMAOANR4A2NR4A1NR4A3
SCHEMBL6978658 0.79 APP (0.60) APPMAOBMAOANR4A2MRGPRX4
SCHEMBL13709217 0.78 NR4A2 (0.43) MAOBMAOANR4A2NR4A1NR4A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349857-B2 Quinazoline derivatives having tyrosine kinase inhibitory activity SHIONOGI & CO., LTD. (JP) 2013-01-08 US disclosed
US-8202879-B2 Quinazoline derivatives having tyrosine kinase inhibitory activity SHIONOGI & CO., LTD. (JP) 2012-06-19 US disclosed
US-20120123114-A1 QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-05-17 US disclosed
US-20090143414-A1 Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity SHIONOGI & CO., LTD. (JP) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143414-A1 Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity ERBB2, EGFR, ABL1 APP 4616/4885MAOB 781/4885MAOA 883/4885
US-20120123114-A1 QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY ERBB2, EGFR, ABL1 APP 4616/4885MAOB 781/4885MAOA 883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.